IP Library Granted Patent US 8,445,254
Granted Patent B2
US 8,445,254 · App. 12/615,872 · Granted May 21, 2013

Regulated expression of antigen and/or regulated attentuation to enhance vaccine immunogenicity and/or safety

Inventors: Roy Curtiss, III (Paradise Valley, AZ); Shifeng Wang (Tempe, AZ); Soo-Young Wanda (Chandler, AZ); Wei Kong (Phoenix, AZ)
Assignees: The Arizona Board of Regents for and on Behalf of Arizona State University; The Washington University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,445,254
App. No.
12/615,872
Granted
May 21, 2013
Kind
B2
Abstract

The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.

Claims (19)

1. A recombinant bacterium capable of the regulated expression of at least one nucleic acid sequence encoding an antigen of interest, and capable of regulated attenuation, wherein the bacterium comprises

a. at least one chromosomally integrated nucleic acid sequence encoding a repressor operably linked to the regulatable promoter P BAD ,

b. a vector comprising a nucleic acid sequence encoding at least one antigen of interest operably linked to a promoter regulated by the repressor, such that the expression of the nucleic acid sequence encoding the antigen is repressed during in vitro growth of the bacterium, but the bacterium is capable of high level expression of the nucleic acid sequence encoding the antigen in a host,

c. a regulatable promoter chromosomally integrated so as to replace the native promoter of, and be operably linked to, at least one nucleic acid sequence of an attenuation protein, and

d. the mutation ΔP crp ::TT ara C P BAD crp.

2. The recombinant bacterium of claim 1 , wherein the repressor is selected from the group consisting of LacI, C2, and C1.

3. The recombinant bacterium of claim 1 , wherein the bacterium comprises at least two chromosomally integrated nucleic acid sequences, wherein at least one chromosomally integrated nucleic acid sequence encodes a repressor operably linked to the regulatable promoter P BAD , and the second chromosomally integrated nucleic acid sequence encodes a repressor operably linked to a regulatable promoter.

4. The recombinant bacterium of claim 3 , wherein the repressors are independently selected from the group consisting of LacI, C2, and C1.

5. The recombinant bacterium of claim 1 , wherein the codons of the nucleic acid sequence encoding the repressor have been modified so as to optimize the expression level of the nucleic acid sequence encoding the repressor.

6. The recombinant bacterium of claim 1 , wherein the repressor comprises a modified Shine-Dalgarno sequence and optimized codons so as to optimize the expression level of the nucleic acid sequence encoding the repressor.

7. The recombinant bacterium of claim 1 , wherein the vector is a plasmid.

8. The recombinant bacterium of claim 1 , wherein the nucleic acid encoding an antigen of interest is operably linked to a promoter regulated by a repressor selected from the group consisting of LacI, C1, and C2.

9. The recombinant bacterium of claim 1 , wherein the nucleic acid encoding an antigen of interest is operably linked to a P trc promoter.

10. The recombinant bacterium of claim 1 , wherein the antigen is toxic.

11. The recombinant bacterium of claim 1 , wherein the vector further comprises a nucleic acid sequence encoding a secretion signal for the antigen of interest.

12. The recombinant bacterium of claim 1 , wherein the bacterium elicits a protective immune response in the host.

13. The recombinant bacterium of claim 1 , wherein the bacterium comprises more than one means of attenuation.

14. The recombinant bacterium of claim 1 , wherein the repressor is LacI; the regulatable promoter is P BAD , the vector is a plasmid; and the nucleic acid encoding an antigen of interest is operably linked to the P trc promoter.

15. A vaccine composition comprising the recombinant bacterium of claim 1 .

Assignments (5)
CONFIRMATORY LICENSE Recorded Jul 11, 2016
From: ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039299/0810 →
CONFIRMATORY LICENSE Recorded Nov 29, 2012
From: ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029374/0342 →
CONFIRMATORY LICENSE Recorded Oct 24, 2012
From: ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029187/0451 →
CONFIRMATORY LICENSE Recorded May 4, 2010
From: ARIZONA STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024333/0560 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2009
From: CURTISS, ROY, III; WANG, SHIFENG; WANDA, SOO-YOUNG; KONG, WEI
To: THE ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY; THE WASHINGTON UNIVERSITY
Reel/Frame 023689/0343 →
Continuity (3)
Continuation In Part PCTUS2008063293 · May 9, 2008
Provisional Application 60917313 · May 10, 2007
Related Publication 20100124558A1 · May 20, 2010